This study aims to describe a patient developing concomitant severe liver failure and lactic acidosis after long-term treatment with linezolid. A 55-year-old Caucasian woman developed concomitant severe liver failure and lactic acidosis after a treatment with linezolid for 50 days because of infected hip prosthesis. Other causes of liver failure and lactic acidosis were excluded by extensive diagnostic workup. A liver biopsy showed microvesicular steatosis. As linezolid toxicity was considered to be the cause of the lactic acidosis and the severe hepatic failure, the antibiotic was withdrawn. After 4 days of supportive therapy and hemodialysis, the serum lactate level returned within normal limits. The prothrombin time ratio and thrombocytes recovered within 2 weeks. Bilirubin levels normalized within 14 weeks. Since no other cause could be identified, liver injury was considered to be drug-related. Resolution of the hepatotoxicity occurred after discontinuation of linezolid, supportive treatment measures, and hemodialysis. Both lactic acidosis and microvesicular steatosis after the use of linezolid are related to mitochondrial dysfunction. The Council for International Organizations of Medical Sciences/Roussel Ucalf Causality Assessment Method scale revealed that the adverse drug event was probable. Prolonged exposure to linezolid may induce severe hepatotoxicity. Clinicians should be aware of this possible adverse effect especially in case of long-term treatment.
Falagas ME, Vardakas KZ (2008) Benefit–risk assessment of linezolid for serious Gram-positive bacterial infections. Drug Saf 31:753–768
Bishop E, Melvani S, Howden BP, Charles PGP, Grayson ML (2006) Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 50:1599–1602
Manfredi R (2006) Update on the appropriate use of linezolid in clinical practice. Ther Clin Risk Manag 2:455–464
Vinh DC, Rubinstein E (2009) Linezolid: a review of safety and tolerability. J Infect 59(S1):S59–S74
William ML (2003) Drug-induced hepatotoxicity. N Engl J Med 349:474–485
Abboud G, Kaplowitz N (2007) Drug-induced liver injury. Drug Saf 30:277–294
Lucena MI, Camargo R, Andrade RJ et al (2001) Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 33:123–130
Garcia-Cortés M, Lucena MI, Pachkoria K et al (2008) Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther 27:780–789
Hussaini SH, Farrington EA (2007) Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 6:673–684
Fromenty B, Pessayre D (1997) Impaired mitochondrial function in microvesicular steatosis. J Hepatol 26:43–53
Fromenty B, Berson A, Pessayre D (1997) Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxidation. J Hepatol 26:13–22
Labbe G, Pessayre D, Fromenty B (2008) Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 22:335–353
McKee EE, Ferguson M, Bentley AT, Marks TA (2006) Inhibition of mammalian mitochondrial protein synthesis. Antimicrob Agents Chemother 50:2042–2049
De Vriese AS, Van Coster A, Smet J et al (2006) Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 42:1111–1117
Garrabou G, Soriano A, Lopez S et al (2007) Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob Agents Chemother 51:962–967
Livermore DM (2000) Quinupristin/dalfopristin and linezolid: where, when, which and whether to use? J Antimicrob Chemother 46:347–350
McKee EE, Ferguson M, Bentley AT et al (2006) Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 50:2042–2049
Brunt EM (2007) Non alcoholic fatty liver disease. In: MacSween RNM, Burt AD, Portmann BC, Ferrell LD (eds) MacSween’s pathology of the liver, 5th edn. Elsevier Health Sciences, Amsterdam, pp 367–398
Ukleya A, Romano MM (2007) Complications of parenteral nutrition. Gastroenterol Clin N Am 36:23–46
Linden P (2007) Safety profile of meropenem. Drug Saf 30(8):657–668
Bibliographic reference
De Bus, Liesbet ; Depuydt, Pieter ; Libbrecht, Louis ; Vandekerckhove, Linos ; Nollet, Joke ; et. al. Severe drug-induced liver injury associated with prolonged use of linezolid. In: Journal of Medical Toxicology : official journal of the American College of Medical Toxicology, Vol. 6, no.3, p. 322-326 (2010)
